Figure 1.

Flowchart of the study protocol. The study comprised two groups: patients undergoing therapy solely with derivatives of 5-aminosalicylic acid (5-ASA) and patients receiving add-on nutraceutical supplementation. Retrospective analysis involved the collection of the partial Mayo score alongside the faecal calprotectin levels and the 5-ASA dose at three months (T₁) and six months (T₂) from the initiation of treatment at T₀ (a retrospective window of six months). Throughout the interval, any reported adverse events were sought in the records.